Skip to main content
OpenTrials
Completed

NCT Number: NCT01237132

East-West Hepatocellular Carcinoma Study Group

The current treatment guidelines of hepatocellular carcinoma (HCC) of the American and European Associations for the Study of Liver Disease are based on the Barcelona-Clinic-Liver-Cancer classification (BCLC), which does not recommend surgery in patients with large, multinodular and macrovascular invasive disease. The aim of this study was to investigate the role of hepatic resection in a large retrospective multicentric cohort of patients resected for HCC regardless of the BCLC indications.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • clinical diagnosis of hepatocellular carcinoma
  • candidate to liver resection as a curative treatment

Exclusion criteria

  • uncertain diagnosis of hepatocellular carcinoma
  • uncertain follow-up data

Treatment and study plan

Primary outcomes

  1. Overall survival of resected patients for HCC

    The primary endpoint of the study was the overall survival of patients resected for HCC in any stage of the BCLC classification.

Secondary outcomes

  1. Disease-free survival of resected patients for HCC

    The secondary endpoint was the disease-free survival of patients resected for HCC among the BCLC stages.

Sponsors and collaborators

Lead sponsor

University of Milan

Other

Registry information

Important dates

First posted
Nov 9, 2010
Registry last updated
Nov 9, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.